Torka, Pallawi
Kambhampati, Swetha
Chen, Lu
Wang, Xiaoguang
Chen, Canping
Vuong, Dan
Qin, Hanjun
Muir, Alexandra http://orcid.org/0000-0003-3346-8892
Orand, Kirsten
Borja, Ivana
Lynne Smith, D.
Herrera, Alex F.
Spurgeon, Stephen E. F.
Park, Byung
Lewis, Lionel D.
Hernandez-Ilizaliturri, Francisco
Xia, Zheng http://orcid.org/0000-0003-3364-8324
Danilov, Alexey V. http://orcid.org/0000-0003-4461-0970
Article History
Received: 20 July 2022
Revised: 27 November 2022
Accepted: 29 November 2022
First Online: 11 January 2023
Competing interests
: AVD has received consulting fees from Abbvie, AstraZeneca, Bayer Oncology, BeiGene, Bristol Meyers Squibb, Genentech, GenMab, Incyte, Lilly Oncology, Nurix, Oncovalent, Pharmacyclics and TG Therapeutics and has ongoing research funding from Abbvie, AstraZeneca, Bayer Oncology, Bristol Meyers Squibb, Cyclacel, MEI Pharma, Nurix and Takeda Oncology. PT has received consulting fees from ADC Therapeutics, Genentech and TG Therapeutics.